Electroacupuncture Pretreatment Alleviates LPS-Induced Acute Respiratory Distress Syndrome via Regulating the PPAR Gamma/NF-Kappa B Signaling Pathway

Feng, Di; Zhou, Huanping; Jin, Xiaohong; Wei, Juan; Zhang, Qingqing; Gu, Yang; Zhang, Pengcheng; Yang, Hao; Song, Jiangang; Shi, Xuan; Lv, Xin

doi:https://doi.org/10.1155/2020/4594631

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Disclosure Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Special Issue

Complementary and Alternative Therapies for Inflammatory Diseases 2020

View this Special Issue

Research Article | Open Access

Volume 2020 | Article ID 4594631 | https://doi.org/10.1155/2020/4594631

Electroacupuncture Pretreatment Alleviates LPS-Induced Acute Respiratory Distress Syndrome via Regulating the PPAR Gamma/NF-Kappa B Signaling Pathway

Di Feng,¹Huanping Zhou,¹Xiaohong Jin,²Juan Wei,¹Qingqing Zhang,¹Yang Gu,¹Pengcheng Zhang,³Hao Yang,¹Jiangang Song,⁴Xuan Shi,¹and Xin Lv¹

Guest Editor: Yuan Xu

Received22 Apr 2020

Revised27 Jun 2020

Accepted30 Jun 2020

Published23 Jul 2020

Abstract

Electroacupuncture (EA) is reported to possess anti-inflammatory properties and has beneficial effects on acute respiratory distress syndrome (ARDS). However, the underlying mechanisms of the effects of EA on ARDS remain unclear. This study aims to investigate the protective effect of EA on LPS-induced ARDS. In this study, Sprague-Dawley male rats were treated with EA at Hegu (LI4) for 45 minutes before LPS instillation (0.4 mg/kg, 100 ul). H&E staining, wet-to-dry weight (W/D) ratio, PaO₂, and protein content in BALF were employed to determine the function of lung tissues. Inflammatory cytokines in serum and BALF were detected by enzyme-linked immunoassay assay (ELISA). The levels of oxidative stress markers were detected to determine the oxidative stress status. Cell apoptosis was observed by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining and western blot. Here, we found that EA pretreatment effectively alleviated lung pathological damage. Moreover, EA suppressed the oxidative stress damage by upregulating glutathione and superoxide dismutase and downregulating malondialdehyde. EA pretreatment also regulated apoptosis-related proteins, such as Bax and Bcl-2. We found that peroxisome proliferators-activated receptors γ (PPARγ) play a critical role during ARDS, EA up-regulated the expression of PPARγ, which inhibited the activation of nuclear factor-kappa B (NF-κB) and decreased the inflammatory cytokines (interleukin-1β, interleukin-6, and tumor necrosis factor-α). When rats were treated with GW9662, a selective PPARγ antagonist, these effects of EA were reversed. Our study demonstrated that EA pretreatment had a beneficial effect on LPS-induced ARDS in rats by anti-inflammatory, antioxidative, and antiapoptotic properties which was regulated via PPARγ/NF-κB signaling pathway.

1. Introduction

Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure. Globally, ARDS accounts for 10% of intensive care unit admissions, representing more than 3 million patients annually [1]. ARDS is characterized by noncardiogenic pulmonary edema, life-threatening hypoxemia, oxidative stress, and imbalance of proinflammatory and anti-inflammatory cytokines [2]. The LUNG SAFE study reported that the mortality rate of ARDS was 34% to 45% [3]. However, there is still no effective therapy for this life-threatening disorder because of the limited understanding about its pathogenesis.

Acupuncture is a popular folk practice in traditional Chinese medicine (TCM) with a history over 5000 years. In Europe and the USA, this traditional Chinese medicine has become one of the treatment strategies and has steadily claimed its usefulness in complementary medicine [4]. Electroacupuncture (EA), a kind of therapy, combines traditional Chinese medicine with modern technique. Increasing numbers of studies have shown that EA has an effect against inflammation. Our previous study [5] found that EA performed at the acupoints Hegu (LI-4, located at the junction of the first and second metacarpal bones) and Neiguan (PC-6, located in the groove caudal to the flexor carpi radialis and cranial to the superficial digital flexor muscles) could inhibit systemic inflammatory response in rats with lethal endotoxemia. Yang et al. [6] reported that acupuncture performed at the acupoints Dazhui (GV14, on the posterior median line in the depression below the spinous process of the seventh cervical vertebra), Fengmen (BL12, 1.5 cun lateral to the lower border of the spinous process of the second thoracic vertebra), and Feishu (BL13, 1.5 cun lateral to the lower border of the spinous process of the third thoracic vertebra) could exert a regulatory effect on mucosal and cellular immunity in patients with allergic asthma. Rafael Torres-Rosas et al. [7] found that EA at acupoint Zusanli (ST36, 2 mm lateral to the anterior tubercle of the tibia in the anterior tibial muscle and 4 mm distal to the knee joint lower point) could reduce the lipopolysaccharide- (LPS-) induced serum level of many cytokines. Other studies have explored the relationship between EA and peroxisome proliferators-activated receptors γ (PPARγ) in patients with Alzheimer’s disease (AD) and type 2 diabetes mellitus (DM2) [8, 9]; thus, it is important to explore the role of PPARγ in the process of ARDS and its crucial role in the EA treatment of ARDS.

PPARγ is a member of ligand-activated transcription factors superfamily PPARs. In the process of lipid metabolism homeostasis, energy homeostasis, and inflammatory response, PPARγ plays a crucial role. Our previous study has shown that PPARγ is one of the key mediators to alleviate Ali. [10], and other investigators also demonstrated that PPARγ plays a critical role in resisting oxidant-induced lung injury [11, 12], reducing inflammation [13] and alleviating pulmonary fibrosis [14] in both mice and humans, suggesting that PPARγ may be a potential therapeutic target for ARDS.

Based on these data, we hypothesized that EA at specific acupoint Hegu (LI-4) could activate PPARγ and inhibit inflammatory cytokines and the inflammatory response in a rat model of ARDS.

2. Materials and Methods

2.1. Animals and Grouping

Male Sprague-Dawley (SD) rats weighing 200–300 g (SLAC Laboratory Animal Co., Ltd., Shanghai, China) were raised in a specific pathogen-free environment for a week in a 12-hour light/dark cycle, constant temperature, and humidity condition with free access to standard rodent diet and water. All animal experiments were approved by the Animal Experiment Administration Committee of the Shanghai Pulmonary Hospital and carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH publications No. 8023, revised 1978). Fifty rats were equally randomized into five groups: negative control (NC) group, where the rats received intratracheal instillation of 100 ul saline by a MicroSprayer syringe assembly (MSA-250-M, Penn Century, USA) according to the previous study [15] and EA pretreatment at nonacupoint for 45 minutes; LPS group, where the rats received intratracheal instillation of lipopolysaccharide (LPS; L2630, Sigma MO, USA, 0.4 mg/kg, 100 ul) by a MicroSprayer syringe assembly and EA pretreatment at nonacupoint for 45 minutes; EA group, where the rats received intratracheal instillation of LPS by a MicroSprayer syringe assembly and 45-minute EA pretreatment at Hegu; R + EA group, where the rats received caudal vein injection of 0.3 mg/kg rosiglitazone (R), followed by 45-minute EA pretreatment at Hegu, then received intratracheal instillation of LPS by a MicroSprayer syringe assembly; and G + EA group, where the rats received caudal vein injection of 0.3 mg/kg GW9662 (G), followed by 45-minute EA pretreatment at Hegu and then received intratracheal instillation of LPS by a MicroSprayer syringe assembly.

2.2. Electroacupuncture Pretreatment

EA pretreatment was performed as previously described [4] at Hegu (LI4) acupoint, which is located at the junction of the first and the second metacarpal bones. A set of nonacupoints located on the ulna side of the metacarpus served as controls. All rats were anesthetized with intraperitoneal 3% 1 ml/kg pentobarbital sodium. After successful induction of anesthesia, stainless needles were inserted into bilateral acupoints of Hegu (LI4) to a depth of 5 mm, fixed by tapes. Stimulation with 4 mA current at a frequency of 2/100 Hz for 45 minutes was delivered using an EA treatment instrument (HANS LH-202, Huawei Co., Beijing, China).

2.3. Histopathology and Immunohistochemistry Analysis

24 hours after LPS instillation, the right upper lungs in the five groups were excised and fixed in 10% PBS buffered formalin for 24 hours at room temperature, embedded in paraffin, cut into 5-μm sections, and then stained with hematoxylin and eosin (H&E) using the standard protocol. For immunohistochemistry of PPARγ, Bax, and Bcl-2, the tissue sections were incubated with the primary antibody against PPARγ (1 : 500, #2435, Cell Signaling Technology, Boston, USA), Bax (1 : 400, #14796, Cell Signaling Technology, Boston, USA), and Bcl-2 (1 : 500, ab182858, Abcam, Cambridge, United Kingdom). After these procedures, sections were washed with PBS three times, followed by the secondary goat antirabbit antibody (Sangon Biotech, Shanghai, China) at room temperature for 1 hour. At last, the lung histopathology and immunohistochemistry analysis were performed by pathologists blinded to experimental grouping using a digital camera (Nikon, Tokyo, Japan).

The severity of lung injury was scored based on the following histologic features as described previously [16]: (a) alveolar congestion, (b) hemorrhage, (c) infiltration or aggregation of neutrophils in the airspace or vessel wall, and (d) thickness of the alveolar wall/hyaline membrane formation. Each item was scored on a 5-point scale as follows: 0 = minimal damage, 1+ = mild damage, 2+ = moderate damage, 3+ = severe damage, and 4+ = maximal damage. The scores were summed to represent the lung injury score (total, 0–16).

2.4. Measurement of PaO₂, the Lung Wet-to-Dry Weight (W/D) Ratio and Protein Content in Bronchoalveolar Lavage Fluid (BALF)

Four hours after LPS instillation, arterial blood (0.5 ml) was drawn through the common carotid artery and analyzed by Stat Profile pHOx (Nova Biomedical, Waltham, MA, USA). Then, the inferior lobe of the right lung was excised and the wet weight was recorded. The lung tissues were dried in a 60°C oven for a week and then the dry weight was recorded. The lung wet-to-dry weight (W/D) ratio was calculated to assess pulmonary edema. The protein content in BALF was measured with a BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.).

2.5. Inflammatory Cytokines Assay

Four hours after LPS instillation, the serum, BALF, and tissue samples were collected to measure the levels of IL-1β, IL-6, TNF-α, and myeloperoxidase (MPO) via commercial enzyme-linked immunosorbent assay (ELISA) kits (BioLegend, San Diego, CA) following the protocols supplied by manufacturers.

2.6. Reactive Oxidative Stress Activity Assay

The levels of malondialdehyde (MDA) and glutathione (GSH) and the activities of superoxide dismutase (SOD) in the rat lung tissues were measured by commercial biochemical kits (Jiancheng Institute of Biotechnology, Nanjing, China) following the protocols supplied by manufacturers.

2.7. Western Blot Analysis

Western blot analysis was performed as previously described [10]. The lung tissues of the rats were prepared 4 hours after LPS instillation; the protein concentrations of all samples were determined using a BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.). Total protein (30 μg) was separated by 10% SDS-PAGE gel and then transferred to a polyvinylidene fluoride membrane (BioRad, Hercules, California, USA). The membrane was blocked with 5% nonfat dry milk for 2 hours at room temperature, followed by incubation with a primary antibody. The antibodies used for western blotting were as follows: β-actin (1 : 1000, 20536-1-AP, Proteintech, Chicago, USA), PPARγ (1 : 1000, #2435, Cell Signaling Technology, Boston, USA), Bax (1 : 1000, #14796, Cell Signaling Technology, Boston, USA), Bcl-2 (1 : 1000, ab182858, Abcam, Cambridge, United Kingdom), p-p65 (1 : 1000, #3033, Cell Signaling Technology, Boston, USA), IκBα (1 : 1000, #4814, Cell Signaling Technology, Boston, USA), and p-IκBα (1 : 1000, #2859, Cell Signaling Technology, Boston, USA). After being washed, the membrane was incubated with the secondary antibody (1 : 5000) for 1 hour at room temperature, washed with TBST, and detected using an ECL chemiluminescence detection kit (Beyotime, P0018A, Shanghai, China) and Quantity One software (Bio-Rad). The density of each specific band was quantified with Image J.

2.8. TUNEL Staining of the Lung

Apoptosis in the lung tissues was assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) using a commercial kit as previously described [17]. Under experimental conditions, lung tissues were fixed in 10% PBS buffered formalin for 25 minutes at 4°C and washed by PBS. 2% Triton X-100 was used to permeabilize. Lung tissues were incubated at 37°C for 60 minutes in equilibration buffer, 2-deoxynucleotide 5′-triphosphate, and terminal deoxynucleotidyl transferase (TdT) enzyme as per manufacturer’s protocol. Then samples were washed in PBS. The sections were observed with a fluorescence microscope, and representative fields were chosen for application.

2.9. Statistical Analysis

All results are presented as the mean ± standard error of the mean (SEM) n = 10 rats/group. The differences between groups were determined using one-way ANOVA with Bonferroni post hoc multiple comparisons test. P values less than 0.05 were considered statistically significant. Statistical analyses were performed with Graph Pad Prism 7 software (La Jolla, CA, USA).

3. Results

3.1. EA Pretreatment Increases the Expression of PPARγ after LPS Instillation

The expression of PPARγ in the rat lung tissues was detected by western blot analysis at 4 hours after LPS instillation. Compared with NC group, LPS instillation decreased the expression of PPARγ, while EA pretreatment upregulated the expression of PPARγ. In the R + EA group, the expression of PPARγ was upregulated, while treated with GW9662, the expression was decreased significantly (Figures 1(a) and 1(b)).

(a)

(b)

(c)

Levels of PPARγ expression were also detected by immunohistochemistry (IHC). In NC group, the expression of PPARγ was abundant and after LPS instillation, the expression of PPARγ was significantly decreased. When pretreated with EA, the downregulation of PPARγ was prevented in the rat lung tissues. The results in IHC were similar to that detected by western blot, in the R + EA group, the expression of PPARγ was upregulated and, in G + EA group, the expression of PPARγ was decreased (Figure 1(c)). These results indicated that EA pretreatment could alleviate the downregulation of PPARγ in the rat lung tissues after LPS instillation.

3.2. EA Pretreatment Alleviates Lung Tissue Injury after LPS Instillation

Because of the changes of PPARγ expression in the above three groups, the agonist and inhibitor of PPARγ, rosiglitazone and GW9662, were used in R + EA group and G + EA group, respectively, before EA treatment and LPS instillation as previously described. The protective effect of EA on the rat lung tissues was evaluated by microscopy. Compared with NC group, acute inflammatory response was observed in the rat lung tissues in LPS group, as represented by the damaged thick alveolar wall, the increased number of inflammatory cells, and the increased amount of vascular congestion (Figure 2(a)). It is noteworthy that EA pretreatment attenuated the pathological changes in the rat lung tissues (Figure 2(b)).

(a)

(b)

(c)

(d)

(e)

The protein content in BALF, the wet-to-dry weight (W/D) ratio of the rat lung tissues and arterial partial pressure of oxygen (PaO₂) were also measured to analyze the lung damage. As can be seen in Figure 2(c), W/D in LPS group was higher than that in NC group, while there was a decrease in W/D in EA and R + EA groups. Measurements of PaO₂ in the five groups indicated that EA relieved the respiratory injury induced by LPS instillation (Figure 2(d)). In addition, the protein content in BALF showed the similar trends (Figure 2(e)). All these results suggested that EA pretreatment effectively relieved ARDS, and the effect of EA could be reversed by PPARγ antagonist GW9662.

3.3. EA Pretreatment Suppresses the Inflammatory Response and Oxidative Stress Damage

During the process of ARDS, the inflammatory response and oxidative stress play critical roles. Thus, it is important to explore the effect of EA on the changes of inflammatory cytokines and oxidative stress markers. Levels of inflammatory cytokines in BALF and serum were detected by ELISA in all groups. As shown in Figures 3(a)–3(c), the concentrations of IL-1β, IL-6, and TNF-α in BALF of LPS group were significantly higher than those in NC group, and EA pretreatment effectively suppressed the production of these inflammatory cytokines. Rosiglitazone treatment reduced the levels of these cytokines and their expressions were almost the same as those in LPS group after GW9662 treatment. As shown in Figures 3(d)–3(f), the serum levels of these three cytokines in LPS group were increased compared with those of NC group, and EA pretreatment lowered their levels. In addition, when PPARγ was activated by rosiglitazone, the expressions of the inflammatory cytokines were downregulated. The level of inflammation in G + EA group was similar to that in LPS group. MPO is highly expressed in neutrophil and the activity of MPO reflects neutrophil infiltration. In this study, MPO activity in lung tissues was elevated in LPS group and reduced in EA group (Figure 3(g)). These results suggested that EA pretreatment could effectively inhibit LPS-induced inflammatory response and this effect could be regulated by PPARγ.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

To clarify the protective effect of EA on oxidative stress damage, the levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH) were detected in the rat lung tissues. MDA was significantly elevated in LPS group compared with those of NC group and EA pretreatment group. The levels of SOD and GSH showed the opposite trend (Figures 3(h)–3(j)). These results suggested that EA pretreatment reduced inflammatory response and oxidative stress damage to prevent ARDS.

3.4. EA Pretreatment Inhibits Cell Apoptosis in the Rat Lung Tissues

Lung injury is known to be associated with cell apoptosis [17, 18]. TUNEL staining was used to determine the antiapoptosis property of EA (Figure 4(a)). It was found that only a very small number of positive TUNEL staining points were detected in the lung tissue in NC group. However, a great number of positive cells were seen diffusely distributed in LPS group. ARDS-induced cell apoptosis was reduced after EA pretreatment as compared with that in LPS group, showing no significant difference between EA and R + EA groups. Moreover, we further detected the expression of Bax and Bcl-2, two critical apoptosis-related proteins, by immunohistochemical staining (Figure 4(a)) and western blot analysis (Figures 4(b) and 4(c)). The immunohistochemical staining results indicated that LPS instillation increased the expression of Bax and decreased the expression of Bcl-2 when compared with NC group. In addition, when PPARγ was activated by rosiglitazone, the expressions of these two proteins were similar to EA group. The levels of these two proteins in G + EA group were similar to that in LPS group. These results indicated that EA pretreatment suppressed cell apoptosis to provide a protective effect in the rat lung tissues after ARDS damage.

(a)

(b)

(c)

(d)

3.5. EA Pretreatment Inhibits NF-κB Expression in LPS-Induced Acute Lung Injury

It was known that PPARγ can directly bind to the subunit p65/p50 of NF-κB to form a transcriptional repressor complex [19]. This complex can reduce the binding activity of NF-κB and suppress the transcription of the downstream genes. To further explore the protective mechanism of EA in ARDS, we detected the expressions of p-p65, p-IκBα, and IκBα via western blot analysis in different groups. As shown in Figure 5, the expression of p-p65 and p-IκBα was upregulated significantly in LPS group when compared with that in NC group, suggesting that LPS activated the NF-κB signaling pathway. However, EA pretreatment suppressed the expression levels of p-p65 and p-IκBα and increased the expression level of IκBα. After treatment with GW9662, the antagonist of PPARγ, the expression levels of these proteins showed similar trends to that in LPS group, which indicated that the activation of NF-κB signaling pathway can be regulated by PPARγ. Therefore, we concluded that EA inhibited the NF-κB pathway via upregulating PPARγ to alleviate ARDS damage.

(a)

(b)

(c)

(d)

4. Discussion

In the present study, we found that EA pretreatment alleviates lung injury in rats ARDS model by reducing inflammatory response, reducing oxidative stress, and decreasing apoptosis. The underlying mechanism involves activating PPARγ and inhibiting NF-κB. These results suggested that EA is a potential therapy to ameliorate LPS-induced ARDS.

ARDS is a kind of respiratory diseases with high mortality, involving uncontrolled systematic inflammatory responses, ROS damage, and cell apoptosis [20]. In this study, we selected acupoint Hegu (LI4) for EA pretreatment as previously described [21] to evaluate the effect of EA in the process of ARDS. The lung histological analysis was similar to our previous study [10], and lung tissues in LPS group were represented as alveolar septal thickening, interstitial edema, and vascular congestion, all of which were relieved by EA pretreatment. Knowing that the protein content in BALF, W/D, and PaO₂ were significantly related to the degree of lung injury [21], we detected these markers in our study and found the protein content in BALF and W/D were increased and PaO₂ was decreased in LPS group, while EA pretreatment decreased BALF and W/D and increased PaO₂ in EA group. In addition, we found that the effect of EA pretreatment could be reversed by PPARγ antagonist GW9662, suggesting that LPS-induced ARDS could be alleviated by EA via the PPARγ-dependent pathway.

It was well known that the pathophysiological process of ARDS is complex, and oxidative stress and inflammation are two major processes which cause ARDS [22]. GSH plays a protective role during the process of oxidative stress damage caused by free radicals and GSH is a good indicator of oxidative stress status and lung injury [23]. SOD catalyze the conversion of superoxide into oxygen and hydrogen peroxide and control the levels of a variety of reactive oxygen species (ROS) and reactive nitrogen species [24]. EA pretreatment alleviated the downregulated levels of GSH and SOD caused by LPS instillation, indicating that EA pretreatment alleviated the oxidative stress in LPS group. MPO is an important peroxidase enzyme to reflect neutrophil infiltration during the process of inflammation [25]. MDA is an end product of lipid peroxidation that can serve as a mediator of both oxidative stress and inflammation, commonly used as a measure of oxidative stress in biological materials [26]. In this study, MPO and MDA activities in rat lung tissue were upregulated in LPS group, and EA pretreatment reduced MPO and MDA activities.

Cell apoptosis plays a critical role in ARDS and previous study demonstrated that free radicals caused by stimulation induce Bax activation and Bcl-2 inhibition and finally cause apoptosis [27]. In this study, TUNEL staining showed the number of TUNEL-positive cells significantly higher in the rat lung tissues in LPS group. EA pretreatment decreases the number of positive cells. Moreover, the expressions of Bax increased and Bcl-2 decreased in LPS group compared with those in NC group. However, EA pretreatment downregulates the expression of Bax and upregulates the expression of Bcl-2.

The relationship between EA and PPARγ has been explored in patients with Alzheimer’s disease (AD) and type 2 diabetes mellitus (DM2) [8, 9] and it was reported that PPARγ played a crucial role in anti-inflammatory activities [28] and activation of PPARγ, which is known to be essential for the inflammation-suppressive effects, like inflammatory cytokine production and mitochondrial activities [29, 30]. However, there is no study reporting how EA affected the PPARγ gene in ARDS. In our previous study [31], we found that PPARγ was involved in M2 macrophage polarization, which showed a protective effect in Ali. In the current study, we also found that the expression of PPARγ was decreased in LPS group and increased with the pretreatment of EA. Meanwhile, the level of inflammation in lung tissues was also opposite to the expression of PPARγ. However, when PPARγ was blocked by GW9662, the effect of EA was obviously decreased. These results were consistent with the possibility that PPARγ downregulation had impact on ARDS and EA may have a protective effect on the injury.

Some investigators found that the anti-inflammatory and organ-protective properties of EA were associated with NF-κB inactivation in some diseases such as middle cerebral artery occlusion and reperfusion (MCAO/R) [32], focal cerebral ischemia [33], DM [34], and acute kidney injury [35]. In this study, we found the expression of IκBα was regulated by PPARγ, while the use of GW9662 decreased the expression of IκBα and increased the expression of p-IκBα. Additionally, the expression of p-p65, a subunit of NF-κB, was similar to the level of p-IκBα. Previous studies have shown that IκBα is the inhibitor of NF-κB and increased NF-κB activity can be achieved by the removal of NF-κB inhibitors [36], and ubiquitous removal of NF-κB inhibitors results in severe inflammation and early postnatal death [37], which were similar to our findings and the expression of the downstream of NF-κB, IL-1β, IL-6, and TNF-α, which are considered to be important in regulating inflammatory response [38]. In this study, we found that the levels of IL-1β, IL-6, and TNF-α in serum and in BALF were significantly increased in LPS group and decreased in EA group. In addition, GW9662 reversed the effects of EA against LPS-induced ARDS.

Several limitations of this study should be considered. Firstly, it is reported that acupuncture has bidirectional regulation effects. In different conditions, acupuncture would play different roles [39, 40]. In order to have a better understanding of the lung protective effects of EA, it is better for us to study the effect of EA on basal lung physiology. Secondly, it is important to choose proper acupoints because acupoint specificity is an important basis for guiding traditional acupuncture practice [41]. Thus, whether EA at other acupoints can show better outcomes remains to be further explored. Thirdly, since EA and rosiglitazone are both the agonist of PPARγ; it is an interesting phenomenon that there are no synergistic effects on suppressing the inflammatory response and oxidative stress damage. Thus, in our further study, we want to use PPARγ knockout mice to verify the protective role of EA on ARDS.

5. Conclusion

In conclusion, this study suggested that EA pretreatment plays a protective role in ARDS; the mechanisms of this effect involve inhibiting inflammatory cytokines, restraining oxidative stress markers and cell apoptosis, and regulating PPARγ activation and NF-κB inactivation in lung tissues. The results demonstrated that EA is a potential therapy to ameliorate ARDS.

Data Availability

The data in this study are available from the corresponding author upon request.

Disclosure

The funders have no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Di Feng, Huanping Zhou, and Xiaohong Jin contributed equally to this work.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81671947 and 81272142) and grants from Shanghai Pulmonary Hospital, 2019, Development Fund of Anesthesiology.

References

E. Fan, D. Brodie, and A. S. Slutsky, “Acute respiratory distress syndrome,” JAMA, vol. 319, no. 7, pp. 698–710, 2018.
View at: Publisher Site | Google Scholar
R. M. Sweeney and D. F. McAuley, “Acute respiratory distress syndrome,” The Lancet, vol. 388, no. 10058, pp. 2416–2430, 2016.
View at: Publisher Site | Google Scholar
G. Bellani, J. G. Laffey, T. Pham et al., “Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries,” JAMA, vol. 315, no. 8, pp. 788–800, 2016.
View at: Publisher Site | Google Scholar
F. J. Zijlstra, I. van den Berg-de Lange, F. J. P. M. Huygen, and J. Klein, “Anti-inflammatory actions of acupuncture,” Mediators of Inflammation, vol. 12, no. 2, pp. 59–69, 2003.
View at: Publisher Site | Google Scholar
J.-g. Song, H.-h. Li, Y.-f. Cao et al., “Electroacupuncture improves survival in rats with lethal endotoxemia via the autonomic nervous system,” Anesthesiology, vol. 116, no. 2, pp. 406–414, 2012.
View at: Publisher Site | Google Scholar
Y.-Q. Yang, H.-P. Chen, Y. Wang, L.-M. Yin, Y.-D. Xu, and J. Ran, “Considerations for use of acupuncture as supplemental therapy for patients with allergic asthma,” Clinical Reviews in Allergy & Immunology, vol. 44, no. 3, pp. 254–261, 2013.
View at: Publisher Site | Google Scholar
R. Torres-Rosas, G. Yehia, G. Peña et al., “Dopamine mediates vagal modulation of the immune system by electroacupuncture,” Nature Medicine, vol. 20, no. 3, pp. 291–295, 2014.
View at: Publisher Site | Google Scholar
M. Zhang, G.-H. Xv, W.-X. Wang, D.-J. Meng, and Y. Ji, “Electroacupuncture improves cognitive deficits and activates ppar-γ in a rat model of Alzheimer’s disease,” Acupuncture in Medicine, vol. 35, no. 1, pp. 44–51, 2017.
View at: Publisher Site | Google Scholar
X. Jing, C. Ou, H. Chen et al., “Electroacupuncture reduces weight gain induced by rosiglitazone through PPARγ and leptin receptor in CNS,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 8098561, 12 pages, 2016.
View at: Publisher Site | Google Scholar
J. Wei, G. Chen, X. Shi et al., “Nrf₂ activation protects against intratracheal LPS induced mouse/murine acute respiratory distress syndrome by regulating macrophage polarization,” Biochemical and Biophysical Research Communications, vol. 500, no. 3, pp. 790–796, 2018.
View at: Publisher Site | Google Scholar
H.-Y. Cho, W. Gladwell, X. Wang et al., “Nrf₂-regulated PPARγ expression is critical to protection against acute lung injury in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 170–182, 2010.
View at: Publisher Site | Google Scholar
J. M. Kaplan, A. Denenberg, M. Monaco, M. Nowell, H. Wong, and B. Zingarelli, “Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock,” Intensive Care Medicine, vol. 36, no. 1, pp. 123–130, 2010.
View at: Publisher Site | Google Scholar
A. Hoetzel, T. Dolinay, S. Vallbracht et al., “Carbon monoxide protects against ventilator-induced lung injury via PPAR-γ and inhibition of egr-1,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 11, pp. 1223–1232, 2008.
View at: Publisher Site | Google Scholar
M. Jain, G. R. S. Budinger, A. Lo et al., “Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-γ,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 11, pp. 1490–1498, 2011.
View at: Publisher Site | Google Scholar
M. Bivasbenita, R. Zwier, H. Junginger, and G. Borchard, “Non-invasive pulmonary aerosol delivery in mice by the endotracheal route,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 61, no. 3, pp. 214–218, 2005.
View at: Publisher Site | Google Scholar
K. Mikawa, K. Nishina, Y. Takao, and H. Obara, “ONO-1714, a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits,” Anesthesia & Analgesia, vol. 97, no. 6, pp. 1751–1755, 2003.
View at: Publisher Site | Google Scholar
D. Jiang, J. Liang, J. Fan et al., “Regulation of lung injury and repair by toll-like receptors and hyaluronan,” Nature Medicine, vol. 11, no. 11, pp. 1173–1179, 2005.
View at: Publisher Site | Google Scholar
G. R. S. Budinger, G. M. Mutlu, D. Urich et al., “Epithelial cell death is an important contributor to oxidant-mediated acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 8, pp. 1043–1054, 2011.
View at: Publisher Site | Google Scholar
S. W. Chung, B. Y. Kang, S. H. Kim et al., “Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB,” Journal of Biological Chemistry, vol. 275, no. 42, pp. 32681–32687, 2000.
View at: Publisher Site | Google Scholar
I. Cortés, O. Peñuelas, and A. Esteban, “Acute respiratory distress syndrome: evaluation and management,” Minerva Anestesiologica, vol. 78, no. 3, pp. 343–357, 2012.
View at: Google Scholar
Z. Wang, L. Hou, H. Yang et al., “Electroacupuncture pretreatment attenuates acute lung injury through α7 nicotinic acetylcholine receptor-mediated inhibition of HMGB1 release in rats after cardiopulmonary bypass,” Shock, vol. 50, no. 3, pp. 351–359, 2018.
View at: Publisher Site | Google Scholar
J. V. Sarma and P. A. Ward, “Oxidants and redox signaling in acute lung injury,” Comprehensive Physiology, vol. 1, no. 3, pp. 1365–1381, 2011.
View at: Google Scholar
S. K. Biswas and I. Rahman, “Environmental toxicity, redox signaling and lung inflammation: the role of glutathione,” Molecular Aspects of Medicine, vol. 30, no. 1-2, pp. 60–76, 2009.
View at: Publisher Site | Google Scholar
Y. Wang, R. Branicky, A. Noë, and S. Hekimi, “Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling,” Journal of Cell Biology, vol. 217, no. 6, pp. 1915–1928, 2018.
View at: Publisher Site | Google Scholar
G. Ndrepepa, “Myeloperoxidase-a bridge linking inflammation and oxidative stress with cardiovascular disease,” Clinica Chimica Acta, vol. 493, pp. 36–51, 2019.
View at: Publisher Site | Google Scholar
C. J. Busch and C. J. Binder, “Malondialdehyde epitopes as mediators of sterile inflammation,” Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1862, no. 4, pp. 398–406, 2017.
View at: Publisher Site | Google Scholar
L. Wang, W. Li, Z. Kang et al., “Hyperbaric oxygen preconditioning attenuates early apoptosis after spinal cord ischemia in rats,” Journal of Neurotrauma, vol. 26, no. 1, pp. 55–66, 2009.
View at: Publisher Site | Google Scholar
M. A. Bouhlel, B. Derudas, E. Rigamonti et al., “PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties,” Cell Metabolism, vol. 6, no. 2, pp. 137–143, 2007.
View at: Publisher Site | Google Scholar
M. Bilban, F. H. Bach, S. L. Otterbein et al., “Carbon monoxide orchestrates a protective response through PPARγ,” Immunity, vol. 24, no. 5, pp. 601–610, 2006.
View at: Publisher Site | Google Scholar
A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001.
View at: Publisher Site | Google Scholar
M. Liu, Y. Chen, S. Wang et al., “α-Ketoglutarate modulates macrophage polarization through regulation of PPARγ transcription and mTORC1/p70S6K pathway to ameliorate ALI/ARDS,” Shock, vol. 53, no. 1, pp. 103–113, 2020.
View at: Publisher Site | Google Scholar
W. Liu, X. Wang, S. Yang et al., “Electroacupunctre improves motor impairment via inhibition of microglia-mediated neuroinflammation in the sensorimotor cortex after ischemic stroke,” Life Sciences, vol. 151, pp. 313–322, 2016.
View at: Publisher Site | Google Scholar
J. Zhan, W. Qin, Y. Zhang et al., “Upregulation of neuronal zinc finger protein A20 expression is required for electroacupuncture to attenuate the cerebral inflammatory injury mediated by the nuclear factor-kB signaling pathway in cerebral ischemia/reperfusion rats,” J Neuroinflammation, vol. 13, no. 1, p. 258, 2016.
View at: Publisher Site | Google Scholar
L. Shi, H. H. Zhang, Y. Xiao, J. Hu, and G. Y. Xu, “Electroacupuncture suppresses mechanical allodynia and nuclear factor kappa B signaling in streptozotocin-induced diabetic rats,” CNS Neuroscience & Therapeutics, vol. 19, no. 2, pp. 83–90, 2013.
View at: Publisher Site | Google Scholar
G. Gu, Z. Zhang, G. Wang et al., “Effects of electroacupuncture pretreatment on inflammatory response and acute kidney injury in endotoxaemic rats,” Journal of International Medical Research, vol. 39, no. 5, pp. 1783–1797, 2011.
View at: Publisher Site | Google Scholar
J. Shen, J. Cheng, S. Zhu et al., “Regulating effect of baicalin on IKK/IKB/NF-kB signaling pathway and apoptosis-related proteins in rats with ulcerative colitis,” International Immunopharmacology, vol. 73, pp. 193–200, 2019.
View at: Publisher Site | Google Scholar
E. G. Lee, D. L. Boone, S. Chai et al., “Failure to regulate TNF-induced NF-kappa B and cell death responses in A20-deficient mice,” Science, vol. 289, no. 5488, pp. 2350–2354, 2000.
View at: Publisher Site | Google Scholar
W. Y. Park, R. B. Goodman, K. P. Steinberg et al., “Cytokine balance in the lungs of patients with acute respiratory distress syndrome,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, pp. 1896–1903, 2001.
View at: Publisher Site | Google Scholar
L. M. Yin, Y. Wang, Y. Wang et al., “Effects of acupuncture on the gene expression profile of lung tissue from normal rats,” Molecular Medicine Reports, vol. 6, no. 2, pp. 345–360, 2012.
View at: Google Scholar
P. Fu, J.-P. Jia, J. Zhu, and J.-J. Huang, “Effects of acupuncture at Neiguan (PC 6) on human brain functional imaging in different functional states,” Zhongguo Zhen Jiu, vol. 25, no. 11, pp. 784–786, 2005.
View at: Google Scholar
G.-X. Shi, X.-M. Yang, C.-Z. Liu, and L.-P. Wang, “Factors contributing to therapeutic effects evaluated in acupuncture clinical trials,” Trials, vol. 13, p. 42, 2012.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2020 Di Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

412

Downloads

716

Citations

Evidence-Based Complementary and Alternative Medicine

Complementary and Alternative Therapies for Inflammatory Diseases 2020

Electroacupuncture Pretreatment Alleviates LPS-Induced Acute Respiratory Distress Syndrome via Regulating the PPAR Gamma/NF-Kappa B Signaling Pathway

Abstract

1. Introduction

2. Materials and Methods

2.1. Animals and Grouping

2.2. Electroacupuncture Pretreatment

2.3. Histopathology and Immunohistochemistry Analysis

2.4. Measurement of PaO2, the Lung Wet-to-Dry Weight (W/D) Ratio and Protein Content in Bronchoalveolar Lavage Fluid (BALF)

2.5. Inflammatory Cytokines Assay

2.6. Reactive Oxidative Stress Activity Assay

2.7. Western Blot Analysis

2.8. TUNEL Staining of the Lung

2.9. Statistical Analysis

3. Results

3.1. EA Pretreatment Increases the Expression of PPARγ after LPS Instillation

3.2. EA Pretreatment Alleviates Lung Tissue Injury after LPS Instillation

3.3. EA Pretreatment Suppresses the Inflammatory Response and Oxidative Stress Damage

3.4. EA Pretreatment Inhibits Cell Apoptosis in the Rat Lung Tissues

3.5. EA Pretreatment Inhibits NF-κB Expression in LPS-Induced Acute Lung Injury

4. Discussion

5. Conclusion

Data Availability

Disclosure

Conflicts of Interest

Authors’ Contributions

Acknowledgments

References

Copyright

2.4. Measurement of PaO₂, the Lung Wet-to-Dry Weight (W/D) Ratio and Protein Content in Bronchoalveolar Lavage Fluid (BALF)